Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives (3)

Amrut Medhekar, Manish Gupta, Nirav Vora

Analysts (7)

Ansh (Capital One), Anubhav Mukherjee (Prescient Capital), Harshal (BTH Capital), Mihir (Fident AMC), Neelam (Perpetuity), Sajal Kapoor (Antifragile Thinking), Vansh Gupta (TCS Capital)

Financials & KPIs

Geographic & Segment Commentary

• Branded Prescription Business (Domestic India): Revenue grew 9% YoY with secondary sales tracking 18.9% growth, ahead of the 11.6% industry. Management is deliberately shifting the portfolio from high-volume, low-margin acute therapies to semi-chronic and specialty segments (gynecology, dermatology, orthopedics), with average monthly sales run rate for new launches almost doubling. Semi-urban push backed by a trained field force is improving market share month-over-month. Maintane (PharmaTrac value ~₹46 crores: ₹34 crores injection, ₹13 crores tablet), Indocap, Endoreg, and Lycored outperformed their therapy markets.

• Hospital Segment (Aequitas Healthcare – new acquisition): 85% stake acquired for ₹20.8 crores at an EV of ~₹25 crores; Aequitas reported FY26 revenue of ₹53 crores. It brings 49 institutional medical representatives, access to 1,000+ hospitals, and relationships with 4,000 specialty doctors, providing immediate entry into the corporate hospital channel. Portfolio is ICU-heavy (latest-generation antibiotics, volume enhancers, peri-operative injectables, pain/antacid), 100% branded with no government tender exposure; top 10 products contribute 50%+ of sales and ~50 hospitals drive most of the revenue.

Company-Specific & Strategic Commentary

• Portfolio Shift to Semi-Chronic/Specialty: Structural repositioning toward higher-value, stickier therapies; new brand launches in the premium tier are generating nearly double the monthly sales run-rate. One first-wave launch completed in Q1; one more expected in Q2.

• Brand Building & Premiumization: Migration from product-centric to brand-centric scientific promotion, with patient-education ecosystems and deeper HCP engagement; brand premium visible in gross margin (65%+) and PAT growth. Brand portfolio including Maintane, Indocap, Endoreg, Lycored, Metadec, Equirex, and Divatrone outperforming respective markets.

• Operational Excellence & People Initiatives: Company-wide "Lean and Green" productivity program; redesigned training, aligned incentive structures, MBA program for sales team, and "Bahubali" rewards system helped reduce attrition and drive behavioral change. PCPM target set upward of ₹2.5 lakhs across four prescription verticals.

• Aequitas Acquisition – Hospital Entry Catalyst: Strategic (not transactional) move; will accelerate JPL power brands (Indocap, Endoreg, Maintane, Eukroma, KTC) into the hospital segment via cross-selling, saving years of market entry time. Integration planning underway; synergies expected to build over next 26 months.

• Capital Allocation & Shareholder Returns: FY22-FY26: EBITDA/PAT grew 2.5x (25% CAGR), free cash flow up 8x, ₹250+ crores operating cash generated; deployed toward Yash Pharma acquisition (₹90 crores), dividends (₹40+ crores), and ₹40 crores buyback. Board recommended 200% dividend including 75% special dividend in May 2026, pending AGM approval.

• Board Changes: Pallavi Dinodia Gupta stepped down (personal commitments); Anil Kumar Matai appointed independent director, bringing 30+ years of pharma/healthcare leadership experience.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

Growth Quality: Primary vs Secondary Sales Gap

• Question: Why did reported revenue grow only 9% vs 18.9% PharmaTrac growth? Is it timing or discounting? (Mihir, Fident AMC)
• Answer: Primary sales (company-to-stockist) always differ from secondary sales (stockist-to-market); statistical representation of under-covered geographies and inventory buffers cause variance. Management is reviewing the magnitude of the gap; guidance of 1.5x industry growth applies to overall business performance. (Manish Gupta)

Aequitas: EBITDA Pathway from ₹50 Lakhs to ₹10 Crores

• Question: How will Aequitas EBITDA scale from ~₹50 lakhs to ₹10 crores? Are promoter salaries dropping off? (Mihir, Fident AMC)
• Answer: Aequitas is a brand and people asset with strong corporate-hospital relationships; JPL power brands will cross-sell into hospitals, adding incremental EBITDA. Promoters retain 15% and will continue leading the business. Pre-identified high-value ICU products (high value per patient/ICU bed) will drive value accretion over 2-3 years; ₹10 crores EBITDA targeted within two years. (Manish Gupta)

Aequitas: Integration Evidence, Challenges, Surprises

• Question: What is the earliest evidence that integration is working, the hardest capability to build, and what has surprised you? (Sajal Kapoor, Antifragile Thinking)
• Answer: No surprises — thorough due diligence preceded the deal; numbers should speak within two quarters. The hardest skill is negotiating win-win propositions with hard-nosed, PE-backed hospital chains; Aequitas' deep relationships with doctors, nursing staff, and purchase teams in corporate hospitals will piggyback JPL brand entry. (Amrut Medhekar)

Aequitas: Product Mix, Working Capital, and Cross-Sell

• Question: What is the product profile, branded vs tender mix, top-10 concentration, cross-sell candidates, and working capital profile? (Neelam, Perpetuity)
• Answer: Product basket spans ICU antibiotics (incl. latest generation), volume enhancers, peri-operative injectables (anesthesia, nutrition), and pain/antacid — all branded, no government tenders. Top 10 products contribute 50%+ of sales; ~50 hospitals drive most revenue. Cross-sell candidates: Indocap, Endoreg, Maintane, Eukroma, KTC. Aequitas will run a longer working capital cycle; subsidiary structure deliberately keeps it separate from JPL's lean cycle. (Amrut Medhekar; Manish Gupta)

Aequitas: Scale and Margin Roadmap

• Question: What scale/margins in two years, and how much from cross-sell vs organic growth? (Neelam, Perpetuity)
• Answer: Targeting ~₹100 crores revenue and ₹10+ crores EBITDA from Aequitas alone within 2.5 years (by FY 2028-29); these are the two numbers management is chasing. (Manish Gupta)

Maintane Scale and Portfolio Concentration

• Question: What is Maintane's MAT, and when does it become large enough to change portfolio-weighted growth? (Ansh, Capital One)
• Answer: PharmaTrac shows Maintane at ~₹46 crores (₹34 crores injection, ₹13 crores tablet), both SKUs growing ahead of the molecule market; it is a top-3 JPL brand and value-accretive. PCPM target is upward of ₹2.5 lakhs, varying across the four prescription verticals. (Amrut Medhekar)

Portfolio: Other Growth Brands

• Question: How do you mitigate Maintane concentration risk, and which other brands can scale? (Harshal, BTH Capital)
• Answer: Metadec, Lycored, Equirex, Divatrone, Endoreg, and PRU are all growing ahead of their markets; prescription growth builds through new-patient journeys and prescriber loyalty over time. (Amrut Medhekar)

Aequitas: Hospital Empanelment and Pipeline

• Question: Which hospital chains and geographies drive the two-year growth plan, and any first-in-India pipeline developments? (Vansh Gupta, TCS Capital)
• Answer: Pan-India presence across top corporate chains including Max, Manipal, Medanta, Cloudnine, Rainbow, and Aster DM. JPL launched one first-wave product in Q1 and expects one more in Q2, prioritizing first-wave (5-10 company) launches rather than blocking first-in-India claims. (Amrut Medhekar)

Working Capital: Step-Change Drivers Since FY24

• Question: What execution habit changed after FY24 to unlock the improvement in cash conversion cycle? (Sajal Kapoor, Antifragile Thinking)
• Answer: No single factor — hundreds of granular initiatives: best-in-class collections discipline, inventory control (the largest driver), strict overdue-debtor management, same-day payment discipline, order-cycle splitting, therapy-classified field deployment, and digital analytics. The principal improvement occurred FY22-FY24 (cash conversion from 59 to 22 days); current readings of 9-11 days are small numbers that magnify percentage swings. (Manish Gupta; Amrut Medhekar)

Aequitas: Gross Margin Profile and Improvement Levers

• Question: Why is Aequitas' gross margin low for a fully branded business, and will improvement come from mix or operating leverage? (Anubhav Mukherjee, Prescient Capital)
• Answer: Hospital procurement is price-first, brand-second, so margins are structurally thinner than prescription business; this will operate as a separate subsidiary. Improvement will come from both productivity gains and a pre-identified pipeline of differentiated/novel products with premium pricing potential; too early (less than a month post-acquisition) to quantify — clarity in coming quarters. (Amrut Medhekar; Manish Gupta)

Key Takeaway

Jagsonpal Pharmaceuticals started FY27 with revenue of ₹82 crores (+9% YoY), operating EBITDA of ~₹19 crores (+21%, 23%+ margin), and PAT of ₹13 crores (+22%), while PharmaTrac secondary sales grew 18.9% against industry growth of 11.6%. The quarter delivered two capital-allocation milestones — completion of the ₹40 crores buyback (3.67x subscribed, ~40% premium) and acquisition of an 85% stake in Aequitas Healthcare for ₹20.8 crores (FY26 revenue ₹53 crores), adding 49 institutional MRs, 1,000+ hospitals, and 4,000 specialty-doctor relationships to create a hospital-segment platform. Strategy centers on semi-chronic/specialty portfolio shifts, brand premiumization (power brands growing 19% vs 16% market), productivity gains, and value-accretive M&A. Management targets 1.5x industry growth and ₹100 crores revenue/₹10+ crores EBITDA from Aequitas within 2.5 years, with key watch points being the primary-versus-secondary sales gap, hospital-segment margin and working-capital dilution, and Maintane concentration.